Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Nodular Melanoma: A Histopathologic Entity?

Green AC, Viros A, Hughes MCB, Gaudy-Marqueste C, Akhras V, Cook MG, Marais R.

Acta Derm Venereol. 2018 Apr 16;98(4):460-462. doi: 10.2340/00015555-2855. No abstract available.

2.

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.

Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC, Marais R.

Eur J Cancer. 2018 Jan;88:1-9. doi: 10.1016/j.ejca.2017.10.029. Epub 2017 Nov 23.

3.

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F.

Ann Oncol. 2018 Jan 1;29(1):30-35. doi: 10.1093/annonc/mdx707.

PMID:
29140430
4.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

5.

Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.

Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel RA.

ESMO Open. 2017 Aug 3;2(3):e000187. doi: 10.1136/esmoopen-2017-000187. eCollection 2017.

6.

Cancer: Tumours addicted to drugs are vulnerable.

Lee RJ, Marais R.

Nature. 2017 Oct 12;550(7675):192-193. doi: 10.1038/nature24148. Epub 2017 Oct 4. No abstract available.

PMID:
28976969
7.

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D.

Nature. 2017 Aug 10;548(7666):239-243. doi: 10.1038/nature23297. Epub 2017 Aug 2.

8.

Molecular analysis of single circulating tumour cells following long-term storage of clinical samples.

Mesquita B, Rothwell DG, Burt DJ, Chemi F, Fernandez-Gutierrez F, Slane-Tan D, Antonello J, Carter M, Carter L, Parry M, Franklin L, Marais R, Blackhall F, Dive C, Brady G.

Mol Oncol. 2017 Dec;11(12):1687-1697. doi: 10.1002/1878-0261.12113. Epub 2017 Oct 24.

9.

New insights into naevoid melanomas: a clinicopathological reassessment.

Cook MG, Massi D, Blokx WAM, Van den Oord J, Koljenović S, De Giorgi V, Kissin E, Grant M, Mandal A, Gremel G, Gaudy C, Viros A, Dhomen N, Khosrotehrani K, Marais R, Green AC, Mihm MC Jr.

Histopathology. 2017 Dec;71(6):943-950. doi: 10.1111/his.13317. Epub 2017 Oct 2.

PMID:
28741688
10.

MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma.

Haston S, Pozzi S, Carreno G, Manshaei S, Panousopoulos L, Gonzalez-Meljem JM, Apps JR, Virasami A, Thavaraj S, Gutteridge A, Forshew T, Marais R, Brandner S, Jacques TS, Andoniadou CL, Martinez-Barbera JP.

Development. 2017 Jun 15;144(12):2141-2152. doi: 10.1242/dev.150490. Epub 2017 May 15.

11.

Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models.

Khandelwal G, Girotti MR, Smowton C, Taylor S, Wirth C, Dynowski M, Frese KK, Brady G, Dive C, Marais R, Miller C.

Mol Cancer Res. 2017 Aug;15(8):1012-1016. doi: 10.1158/1541-7786.MCR-16-0431. Epub 2017 Apr 25.

PMID:
28442585
12.

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Tang H, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R.

Nat Commun. 2017 Apr 18;8:14909. doi: 10.1038/ncomms14909.

13.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BMJM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2017 Mar 13;31(3):466. doi: 10.1016/j.ccell.2017.02.007. No abstract available.

14.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

15.

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.

Delgado-Goni T, Miniotis MF, Wantuch S, Parkes HG, Marais R, Workman P, Leach MO, Beloueche-Babari M.

Mol Cancer Ther. 2016 Dec;15(12):2987-2999. Epub 2016 Oct 7.

16.

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.

Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ.

Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.

17.

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R.

Ann Oncol. 2016 Oct;27(10):1959-65. doi: 10.1093/annonc/mdw278. Epub 2016 Aug 8.

18.

So You Can Teach Old Fibroblasts New Tricks.

Virós A, Girotti MR, Marais R.

Cancer Discov. 2016 Jun;6(6):581-3. doi: 10.1158/2159-8290.CD-16-0503.

19.

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F.

Ann Oncol. 2016 Aug;27(8):1443-8. doi: 10.1093/annonc/mdw192. Epub 2016 May 3.

PMID:
27143638
20.

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors.

Korfi K, Smith M, Swan J, Somervaille TC, Dhomen N, Marais R.

Cell Death Dis. 2016 Apr 7;7:e2177. doi: 10.1038/cddis.2016.70.

21.

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C.

Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003.

22.

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, Baenke F, Pedersen M, Rogan J, Swan J, Smith M, Fusi A, Oudit D, Dhomen N, Brady G, Lorigan P, Dive C, Marais R.

Cancer Discov. 2016 Mar;6(3):286-99. doi: 10.1158/2159-8290.CD-15-1336. Epub 2015 Dec 29.

23.

RETROSPECTIVE. Christopher Marshall (1949-2015).

Marais R.

Science. 2015 Nov 27;350(6264):1040. doi: 10.1126/science.aad8404. No abstract available.

PMID:
26612942
24.

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells.

Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, Viros A, Martin M, Galbraith L, Girotti MR, Dhomen N, Gottlieb E, Marais R.

Mol Oncol. 2016 Jan;10(1):73-84. doi: 10.1016/j.molonc.2015.08.003. Epub 2015 Aug 20.

25.

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis e Sousa C.

Cell. 2015 Sep 10;162(6):1257-70. doi: 10.1016/j.cell.2015.08.015. Epub 2015 Sep 3.

26.

A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.

Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, Viros A, Gesbert F, Delmas V, Rambow F, Bastian BC, Campbell AD, Colombo S, Puig I, Bellacosa A, Sansom O, Marais R, Van Kempen LC, Larue L.

Nat Commun. 2015 Aug 26;6:8093. doi: 10.1038/ncomms9093.

27.

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, Timpson P, Leach J, McGarry L, Shanks E, Bailey P, Chang D, Oien K, Karim S, Au A, Steele C, Carter CR, McKay C, Anderson K, Evans TR, Marais R, Springer C, Biankin A, Erler JT, Sansom OJ.

EMBO Mol Med. 2015 Aug;7(8):1063-76. doi: 10.15252/emmm.201404827.

28.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

29.

Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.

Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E.

Cancer Cell. 2015 Apr 13;27(4):574-88. doi: 10.1016/j.ccell.2015.03.008.

30.

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.

Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TC, Marais R.

Ann Oncol. 2015 Jun;26(6):1180-7. doi: 10.1093/annonc/mdv110. Epub 2015 Feb 23.

31.

BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ.

Mol Ther. 2015 May;23(5):931-942. doi: 10.1038/mt.2015.15. Epub 2015 Jan 26.

32.

Onco-STS: a web-based laboratory information management system for sample and analysis tracking in oncogenomic experiments.

Gavrielides M, Furney SJ, Yates T, Miller CJ, Marais R.

Source Code Biol Med. 2014 Dec 5;9(1):25. doi: 10.1186/s13029-014-0025-z. eCollection 2014.

33.

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11. Erratum in: Cancer Cell. 2017 Mar 13;31(3):466.

34.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2014 Oct 28;12:277. doi: 10.1186/s12967-014-0277-z.

35.

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C.

Cancer Discov. 2014 Oct;4(10):1214-1229. doi: 10.1158/2159-8290.CD-13-1007.

36.

No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Girotti MR, Saturno G, Lorigan P, Marais R.

Mol Oncol. 2014 Sep 12;8(6):1140-58. doi: 10.1016/j.molonc.2014.07.027. Epub 2014 Aug 15. Review.

37.

Hooked on UVR.

Viros A, Marais R.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1009-10. doi: 10.1111/pcmr.12305. Epub 2014 Oct 6. No abstract available.

PMID:
25124536
38.

(G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis.

Pedersen M, Viros A, Cook M, Marais R.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1162-6. doi: 10.1111/pcmr.12293. Epub 2014 Aug 12. No abstract available.

PMID:
25043451
39.

Diverse matrix metalloproteinase functions regulate cancer amoeboid migration.

Orgaz JL, Pandya P, Dalmeida R, Karagiannis P, Sanchez-Laorden B, Viros A, Albrengues J, Nestle FO, Ridley AJ, Gaggioli C, Marais R, Karagiannis SN, Sanz-Moreno V.

Nat Commun. 2014 Jun 25;5:4255. doi: 10.1038/ncomms5255.

40.

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.

Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R.

Nature. 2014 Jul 24;511(7510):478-482. doi: 10.1038/nature13298. Epub 2014 Jun 11.

41.

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.

Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, Gavrielides M, Xing W, Gore M, Larkin J, Marais R.

Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8. doi: 10.1111/pcmr.12279. Epub 2014 Jun 30.

PMID:
24913711
42.

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J.

Nat Commun. 2014 May 22;5:3901. doi: 10.1038/ncomms4901.

43.

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R.

Sci Signal. 2014 Mar 25;7(318):ra30. doi: 10.1126/scisignal.2004815.

PMID:
24667377
44.

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R.

Ann Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6.

45.

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

Gentien D, Kosmider O, Nguyen-Khac F, Albaud B, Rapinat A, Dumont AG, Damm F, Popova T, Marais R, Fontenay M, Roman-Roman S, Bernard OA, Stern MH.

Leukemia. 2014 Jun;28(6):1355-7. doi: 10.1038/leu.2014.28. Epub 2014 Jan 17. No abstract available.

PMID:
24434863
46.

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.

Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1.

47.

Braking BRAF: AMPK leaves ERK stranded in the desert.

Martin M, Marais R.

Mol Cell. 2013 Oct 24;52(2):155-6. doi: 10.1016/j.molcel.2013.10.011.

48.

Transonic, thermodilution, or ionic dialysance to manage vascular access: which method is best?

Badr B, Bories P, Marais R, Frat B, Seigneuric B, Longlune N, Kamar N, Maggioni S, Rostaing L.

Hemodial Int. 2014 Jan;18(1):127-35. doi: 10.1111/hdi.12092. Epub 2013 Sep 9.

PMID:
24016391
49.

SF3B1 mutations are associated with alternative splicing in uveal melanoma.

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R.

Cancer Discov. 2013 Oct;3(10):1122-1129. doi: 10.1158/2159-8290.CD-13-0330. Epub 2013 Jul 16.

50.

Mind the IQGAP.

Sanchez-Laorden B, Viros A, Marais R.

Cancer Cell. 2013 Jun 10;23(6):715-7. doi: 10.1016/j.ccr.2013.05.017.

Supplemental Content

Loading ...
Support Center